Aquestive Therapeutics Inc. Common Stock (AQST)
Stock · NASDAQ · Health Care
$3.77as of 10/16/2026
Price chart
Active signals
AQST Signal Track Record
How signals performed across all stocks →What AQST's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -1.4% | 44% | September 18, 2026 |
| Bollinger Band Breakout | 27 | -3.6% | 44% | August 25, 2026 |
| Bollinger Band BreakdownActive now | 20 | +1.0% | 55% | July 23, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +13.0% | 100% | August 20, 2026 |
| Any 20-session window (baseline) | +1.2% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; S…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 147
- Website
- aquestive.com/
Fundamentals
- 1-day range
- $3.75$4.1
- Market cap
- $491.83M
- P/E (trailing)
- —
- P/E (forward)
- -6.63
- EPS (trailing)
- $-0.65
- Dividend yield
- —
- Beta
- 1.51
- Avg. volume
- 2.71M
How Aquestive Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Aquestive Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027benzinga · 10/15/2026
- Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's SuccessSeekingAlpha · 9/30/2026
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard DalyYahoo · 9/29/2026
- Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy TreatmentBenzinga · 9/17/2026
- Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmYahoo · 9/17/2026
Insider Activity
Insider Actions →- Daniel Barber · September 15, 2026 · Sale25.0K @ $4.82
- Sherry Korczynski · September 9, 2026 · Option Exercise8.8K @ $2.65
- Sherry Korczynski · September 9, 2026 · Sale8.8K @ $5.22
- Peter E. Boyd · September 9, 2026 · X2.3K @ $0.96
- Daniel Barber · September 8, 2026 · X91.7K @ $0.96
- Cassie Jung · September 3, 2026 · X4.6K @ $0.96
- Daniel Barber · August 17, 2026 · Sale25.0K @ $4.29
- Sherry Korczynski · August 14, 2026 · Tax Withholding2.7K @ $4.25
- Daniel Barber · July 16, 2026 · Sale20.4K @ $4
- Daniel Barber · July 15, 2026 · Sale4.6K @ $4.03
- Julie Krop · June 23, 2026 · Sale25.0K @ $5.02
- Julie Krop · June 23, 2026 · Option Exercise25.0K @ $0.7132
- Daniel Barber · June 15, 2026 · Sale25.0K @ $4.16
- Julie Krop · June 10, 2026 · Grant50.5K
- Jenkins Abigail L. · June 10, 2026 · Grant50.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 69.07M
- Total value held
- $281.95M
- Institutional holders
- 176
- Unknown9.81M
- Unknown7.51M
- Unknown7.43M
- Unknown2.94M
- Unknown2.90M
- Unknown2.55M
- Unknown2.50M
- Unknown2.41M
- Unknown2.41M
- Unknown1.92M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Aquestive Therapeutics Appoints Richard Daly to Board
Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.
Aquestive Therapeutics Appoints Richard Daly to Board. Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.